GRI Bio, Inc. 8-K

What Happened

• On January 8, 2026, GRI Bio, Inc. filed a Current Report on Form 8-K to announce additional data from its Phase 2a clinical trial of GRI-0621 in patients diagnosed with idiopathic pulmonary fibrosis (IPF). The company issued a press release reporting the new data; that press release is attached to the 8-K as Exhibit 99.1 and is incorporated by reference.

Key Details

• Filing date: January 8, 2026 (Form 8-K, Item 8.01 — Other Events).
• Subject: Additional data from the Company’s Phase 2a trial of GRI-0621 in IPF.
• Disclosure vehicle: Press release attached as Exhibit 99.1 to the Form 8-K.
• Report signed on behalf of GRI Bio by Leanne Kelly, Chief Financial Officer.

Why It Matters

• Clinical data releases are material for investors because they provide information on a drug candidate’s progress, safety and potential efficacy, which can affect the company’s development timeline and valuation. This 8-K confirms the company is publicly disclosing new Phase 2a information for GRI-0621; investors should read the attached press release (Exhibit 99.1) for the specific results and monitor future regulatory and clinical updates.